China Resources Boya Bio-pharmaceutical Group: Revenue up, profit down sharply; divestment and smart factory support core blood business
Less than 1 min read
Revenue grew 18.7% year-over-year, but net profit fell 71.6% due to asset impairments and weak non-core segments. The company divested loss-making businesses, increased dividends, and advanced smart factory projects to strengthen its core blood products focus.
Original document: China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A [300294] Earnings Release — Mar. 21 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr